当前位置: X-MOL 学术Pharmacol. Therapeut. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
Pharmacology & Therapeutics ( IF 13.5 ) Pub Date : 2020-09-25 , DOI: 10.1016/j.pharmthera.2020.107694
Mu-Yang Huang 1 , Xiao-Ming Jiang 1 , Bing-Lin Wang 2 , Yang Sun 2 , Jin-Jian Lu 1
Affiliation  

Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade has been approved as the standard-of-care for the treatment of non-small cell lung cancer (NSCLC). Yet, the population of patients who benefit from the treatment remains modest, some of whom would get relapsed and progressed eventually. Combination therapy has emerged as an effective way to broaden beneficiaries from PD-1/PD-L1 immunotherapy and overcome or delay the resistance. In this review, we discuss the PD-1/PD-L1 blockade in combination with conventional chemotherapy, targeted therapy or immunotherapy. Meanwhile, we illustrate their underlying mechanisms in regulating the process of the cancer-immunity cycle, providing the rationale for the PD-1/PD-L1 blockade-based combination therapy. The challenges of combination regimens are also addressed.



中文翻译:

PD-1/PD-L1 阻断联合治疗非小细胞肺癌:策略和机制

程序性细胞死亡-1 (PD-1)/程序性死亡配体 1 (PD-L1) 阻断剂已被批准为治疗非小细胞肺癌 (NSCLC) 的标准治疗方法。然而,受益于治疗的患者人数仍然不多,其中一些人最终会复发并进展。联合疗法已成为扩大 PD-1/PD-L1 免疫疗法的受益者并克服或延迟耐药性的有效方法。在这篇综述中,我们讨论了 PD-1/PD-L1 阻断联合常规化疗、靶向治疗或免疫治疗。同时,我们阐明了它们在调节癌症-免疫循环过程中的潜在机制,为基于 PD-1/PD-L1 阻断的联合治疗提供了理论依据。还解决了联合方案的挑战。

更新日期:2020-09-25
down
wechat
bug